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ARTICLE
Primary Care Prescription Drug Use and Related 
Actionable Drug-Gene Interactions in the Danish 
Population
Carin Adriana Theodora Catharina Lunenburg1,2,*, Alexander Sebastian Hauser3, Kazi Ishtiak-Ahmed1,2 and Christiane Gasse1,2,4
Pharmacogenetics (PGx) aims to improve drug therapy using the individual patients’ genetic make-up. Little is known about 
the potential impact of PGx on the population level, possibly hindering implementation of PGx in clinical care. Therefore, we 
investigated how many patients use actionable PGx drugs, have actionable genotypes or phenotypes and which patients 
could benefit the most of PGx testing. We included PGx recommendations from two international PGx consortia (Clinical 
Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG)). Using data 
from publically accessible sales information drawn from the Danish Register of Medicinal Product Statistics (MEDSTAT), we 
identified the number of users of actionable prescription PGx drugs among the total Danish population in 2017. We estimated 
actionable genotypes or phenotypes based on reported frequencies from literature. We identified 49 drug-gene interactions 
related to 41 unique prescription drugs. The estimated median frequency of actionable genotypes or phenotypes among 
prescription drug users was 25% (interquartile range 7–26%). Six of 41 drugs were used more than twice as much in women. 
Actionable PGx drugs were most frequently used by 45–79 year old patients (62%), followed by 25–44 year old patients (18%). 
Almost half of the actionable PGx drugs (19/41) were psychotropics (i.e., antidepressants, antipsychotics, or psychostimu-
lants). PGx testing can have a substantial impact on the population, as one in four prescription drug users has an actionable 
genotype or phenotype and could thus benefit from PGx testing. We advocate for prospective panel-based PGx testing at the 
time of the first PGx drug prescription (“as needed”), with PGx results ready prior to start of the first, and all future, therapies.
Many commonly used drugs are affected by variability in 
drug metabolism and response, potentially contributing to 
treatment failure and increasing the risk of adverse events. 
Examples are antidepressants, proton-pump inhibitors, 
statins, and anticoagulants.1–5 Many drugs are metab-
olized by cytochrome P450 enzymes, such as CYP2D6 
and CYP2C19, which have great variability in activity.6,7 
Pharmacogenetics or pharmacogenomics (PGx) comprise 
the study of genetic variation leading to changes in, for 
example, enzymes, transporters, or receptors, potentially 
resulting in different drug responses. One of the aims of 
practicing PGx is to utilize genetic information to predict 
treatment response in the individual patient, thereby im-
proving drug effectiveness and reducing the risk of adverse 
events. The generalized terms gene-drug interaction or 
drug-gene interaction (DGI) are used to describe the inter-
action between specific genes with specific drugs. Genes 
technically do not interact with drugs directly, but they are, 
for example, encoded to proteins, which, in turn, influence 
drug metabolism. Most of PGx research and guidelines 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Little is known about the potential impact of pharmacoge-
netics (PGx) among outpatient prescription drug users. Two 
prior publications have investigated PGx on large scale lev-
els, but could not include data of a whole population.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  What is the number of patients who use actionable PGx 
prescription drugs, how many of them have actionable 
genotypes or phenotypes, and who could benefit most 
of PGx testing?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The study provides a real-world estimation of the num-
ber of people using prescription PGx drugs in the Danish 
population.
HOW MIGHT THIS CHANGE CLINICAL PHARMA COL-
OGY OR TRANSLATIONAL SCIENCE?
✔  This study will help understand the clinical impact of 
PGx on the population level, which benefits implemen-
tation of PGx in clinical care and improves current drug 
therapy.
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comprise pharmacokinetics (PK; e.g., an altered drug me-
tabolism). Yet, pharmacodynamics (PD; e.g., altered drug 
targets or receptors), are also studied in PGx.8 As many of 
the gene-affected drugs are frequently used, PGx testing 
improving the treatment outcomes of the individual can 
have a major impact on the healthcare system at population 
level, with a potential to reduce costs caused by insufficient 
treatment response and adverse events. This ultimately im-
proves patients’ quality of life.
Literature on PGx has increased exponentially over the last 
2 decades, with currently over 29,000 publications on PGx 
published, yet little is known about the current implementa-
tion of PGx on the population level and the potential impact 
of PGx (e.g., improved health care or reduced costs).9–11
Moreover, it is known that not all genetic variations will 
have clinical impact and thereby not all DGIs are action-
able. Evidence for clinical benefit of a dose adjustment 
differs per DGI and has been derived from studies, ranging 
from prospective clinical data to ex vivo data. “Actionable 
PGx” refers to drugs or specific genotypes or phenotypes 
for which dosing recommendations in PGx guidelines are 
available. For nonactionable DGIs, dose adjustments are 
not expected to improve treatment response. Guidelines for 
dose adjustments are made available by international con-
sortia (e.g., the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and Dutch Pharmacogenetics Working 
Group (DPWG) of the Royal Dutch Pharmacist’s Association). 
These guidelines are built by systematic and peer-review of 
the available literature.12–14 Previously, the DPWG and CPIC 
have each provided, largely overlapping, guidelines for 54 
and 40 actionable DGIs, respectively.12–15 Despite these 
guidelines, clinical implementation has not been optimized 
yet. Several barriers to the implementation of PGx testing 
have been identified, such as limited data on clinical va-
lidity and utility, limited data on (cost-) effectiveness or a 
low positive predictive value of the test.16 In addition, the 
availability of non-PGx tests, such as therapeutic drug mon-
itoring,17 could be argued as an alternative and competing 
option for dose adjustments. Yet, the power of PGx lies in 
the prospective identification of patients at risk (i.e., prior 
to start of therapy), instead of a reactive way to identify ge-
netic variants in patients who already were exposed to the 
risk of decreased drug effectiveness or increased toxicity. 
Pre-emptive PGx testing means to have PGx results ready 
at the point of prescribing a drug, whereas the term reac-
tive testing is used to describe testing in anticipation of drug 
prescriptions (“as needed”) or in response to unexplained 
adverse effects.18–21
Based on the limited available information within the field 
to date, it is still largely unknown what the impact of PGx 
could be on the population level. Therefore, we aimed to 
visualize the possible impact of PGx by answering how 
many patients use actionable PGx drugs, what is the es-
timated proportion of people with actionable genotypes or 
phenotypes, and who could benefit the most in terms of in-
dications of use or sociodemographic characteristics with 
regard to potential sex and age differences. The latter may 
add information if PGx testing could best be applied at a 
specific age.
METHODS
Study population
We identified all users of actionable PGx prescription drugs 
among the total Danish population of 5,748,769 inhabitants 
in 2017.
Data sources
In this study, “actionable” PGx drugs refer to drugs or 
specific genotypes or phenotypes for which dosing recom-
mendations according to CPIC or DPWG PGx guidelines 
are available, and, thus, imply a clinically relevant change 
from standard practice. Data of actionable PGx drugs were 
extracted from MEDSTAT (www.medst at.dk). MEDSTAT is 
a publicly accessible web-service based on data of the 
Register Medicinal Products Statistics. It was established 
in 1994 and includes information on redeemed prescription 
drugs at pharmacies, as well as aggregated data on drug 
sales to all hospitals in Denmark.22–24 Because all data are 
aggregated, single person identification is not possible 
and no informed consent or ethical approval is required. 
The data can be searched by levels of the anatomic ther-
apeutic chemical classification system or product names 
for each drug.25 Aggregated (outcome) measures of drug 
consumption can be chosen as turnover, paid reim-
bursement, volume sold (per 1,000 inhabitants per day), 
and number of users (per 1,000 inhabitants). Due to the 
setup of the data, it is not possible to identify new users 
(incidence). Moreover, it is possible to stratify include or 
exclude these measures according to calendar year, sex, 
age groups, geographic regions of Denmark, and primary 
or hospital sector. For hospital sector data only turnover 
and volume sold were available, not linked to sex or age. 
We extracted number of users of actionable PGx drugs in 
the primary sector (as defined below) for the whole pop-
ulation of Denmark and stratified by sex and age groups 
0–17, 18–24, 25–44, 45–64, 65–79, and 80 years or older. 
Users are defined as anyone having redeemed at least one 
prescription for the drugs of interest in 2017.
Actionable drug-gene interactions
The DGIs or drugs investigated in this study were searched 
using the PharmGKB website, where, among others, 
CPIC and DPWG recommendations are listed.26,27 The 
PharmGKB website lists “clinical guideline annotations,” 
which contain dosing guidelines, “drug label annotations,” 
containing PGx information approved by organizations 
such as the US Food and Drug Administration (FDA), and 
“clinical or variant annotations,” which summarize sup-
portive evidence for DGIs. In this study, we only focused 
on clinical guideline annotations. Additionally, the origi-
nal CPIC and DPWG guidelines were checked to assure 
correct and complete guidelines.28,29 We identified 134 
unique possible DGIs of 99 unique drugs. After exclusion 
of “no DGI” and “not actionable interaction,” 87 actionable 
DGIs (68 unique drugs) remained and were searched in 
MEDSTAT. An overview of the drugs and genes from these 
actionable DGIs, together with relevant drug and disease 
clusters, is shown in Figure 1. There was no information 
on 27 of 68 searched drugs in MEDSTAT. Therefore, a 
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total of 49 DGIs (41 drugs) were included in this study. An 
overview of the included and excluded DGIs is shown in 
Figure 2.
Defined genotype-phenotype frequencies
Genetic variation in PK-related PGx guidelines is often trans-
lated into a phenotype prediction (e.g., poor or extensive 
Figure 1 Overview of actionable drug-gene interactions (DGIs). Shown is a representation of all 87 actionable DGIs in pharmacogenetics 
(PGx; 68 unique drugs), including disease area and associated genes. In total, 49 actionable DGIs (41 unique drugs) were included 
in the actionable PGx drug list in this study. These drugs are shown in bold and marked with an * in the fourth text column (Drug). In 
addition, these drugs are color-coded in orange instead of yellow in the third colored waves column (between Drug group and Drug). 
All CYP genes are colored blue, and non-CYP genes are green with the intention to improve readability of the figure. The figure has 
no scale. CVD, cardiovascular disease.
Anatonomical
system
Disease/
indication
Drug group Drug Gene
Blood and 
blood forming 
organs
Cardiovascular
Disease of 
organs
Genetic
disorder
Immune
system
Metabolic
Musculoskeletal 
system
Neoplasm
Nervous
system
Reproductive
system
Symptom
Acute hyperuricemia
Anaesthesia/surgery
Autoimmune diseases
CVD
Cystic Fibrosis
Epilepsy
Gaucher disease
Gout
Heart
Hepatitis C
Hormone
Hyperlipidemia
Hypertension
Immune-modulation
Infection
Nausea
Neoplasm
Pain
Post-surgery or -injury
Psychiatry
Stomach
Surgery
Analgesic
Anesthetic
Anti-bacterials
Anti-estrogen
Antiarrhythmic
Antidepressant (SSRI/SNRI)
Antidepressant (TCA)
Antiemetic
Antiepileptic
Antigout preparation
Antihypertensive
Antimycotics
Antineoplastic agent
Antipsychotic
Antithrombotic
Antiviral
CFTR potentiator
Cholesterol-lowering
Contraceptives
Detoxificants in oncolytics
Glucosylceramide synthase inhibitor
Immunostimulant
Immunosuppressive
Muscle relaxant
Proton pump inhibitors
Psychostimulant
Abacavir
Acenocoumarol
Allopurinol*
Amitriptyline*
Aripiprazole*
Atazanavir
Atomoxetine*
Atorvastatin*
Azathioprine*
Brexpiprazole
Capecitabine
Carbamazepine*
Citalopram*
Clomipramine*
Clopidogrel*
Codeine*
Desflurane
Desipramine
Doxepin*
Efavirenz
Eliglustat
Enflurane
Escitalopram*
Estrogens*
Flecainide*
Flucloxacillin*
Fluorouracil*
Fluvoxamine*
Haloperidol*
Halothane
Imipramine*
Irinotecan
Isoflurane
Ivacaftor
Lamotrigine*
Lansoprazole*
Mercaptopurine
Methoxyflurane
Metoprolol*
Nortriptyline*
Omeprazole*
Ondansetron*
Oxcarbazepine*
Pantoprazole*
Paroxetine*
Peginterferon alfa-2a
Peginterferon alfa-2b
Phenprocoumon*
Phenytoin
Pimozide*
Propafenone*
Rasburicase
Ribavirin
Sertraline*
Sevoflurane
Simvastatin*
Suxamethonium
Tacrolimus*
Tamoxifen*
Tegafur
Tioguanine
Tramadol*
Trimipramine
Tropisetron
Venlafaxine*
Voriconazole*
Warfarin*
Zuclopenthixol*
CACNA1S
CFTR
CYP2B6
CYP2C19
CYP2C9
CYP2D6
CYP3A5
CYP4F2
DPYD
F5/FvL
G6PD
HLA-A
HLA-B
IFNL3
NUDT15
RYR1
SLCO1B1
TPMT
UGT1A1
VKORC1
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metabolizer) or into a gene activity score. These phenotype 
predictions are used to “quantify” any genetic variation, 
which includes, for example, single nucleotide polymor-
phisms or copy number variations. Frequencies of poor 
metabolizers, intermediate metabolizers, extensive metab-
olizers, and (ultra)rapid metabolizers (UM) of the enzymes 
included in this study were estimated using previously 
published studies.9,10,29–33 SLCO1B1 phenotypes were de-
scribed as poor, intermediate, or normal transporter activity, 
VKORC1 phenotypes as either high or normal sensitivity, 
HLA phenotypes as carrier or noncarriers per associated 
variant, and CYP3A5 phenotypes as nonexpressers, het-
erozygous expressers, and homozygous expressers. For 
each actionable DGI, the dosing guidelines were consulted 
to determine which phenotypes had to be included in the 
calculations of actionable or nonactionable phenotypes, 
because actionable phenotypes can differ per action-
able DGI.28,29 Phenotypes are mutually exclusive, and the 
summed frequencies of actionable phenotypes were used 
to calculate an expected number of users who require a 
treatment or dose adjustment. Figure 3 and Table S1 show 
which phenotypes are actionable according to DPWG or 
CPIC guidelines. In case of discrepancies between guide-
lines, we chose the most inclusive guideline, and did not 
prefer one consortium over the other.15 The identified phe-
notypes were taken into account in the calculations for 
the number of drug users of actionable DGIs who would 
require a dose adjustment. The estimated frequencies of 
actionable and nonactionable phenotypes per enzyme are 
shown in Table 1. Due to the fact that the Danish population 
was investigated in this study with a majority of persons 
(92.3%) with European or Western ancestry,34 frequen-
cies of white patients from literature were applied in these 
calculations.9,10,29–33,35
Microsoft Excel 2010 (Redmond, WA) was used to list and 
calculate extracted numbers of users, frequencies, means, 
medians, interquartile ranges, and to create the heat-map 
colors. Graphics were created in Python (version 3.7.3, 
Python Software Foundation, Wilmington, DE) and package 
plotly (version 4.1.1, Python Software Foundation).
RESULTS
Actionable drug-gene interactions
All 87 identified actionable DGIs, including drug groups and 
indications of each drug, are presented in Figure  1. We 
identified all users of prescription drugs of 49 DGIs within 
the entire Danish population in 2017.34 Figure  4 displays 
for each DGI the (i) total number of drug users, (ii) total 
estimated number of users with an actionable genotype 
or phenotype, (iii) the estimated frequency of actionable 
genotype or phenotypes, (iv) sex ratio in favor of women, 
and (v) estimated number of users with an actionable gen-
otype or phenotype per age group. Individuals can occur 
in more than one drug class or subcategory within drug 
classes. The total number of users in 2017 varied from 
10 for tacrolimus to 341,395 for users of simvastatin. The 
median frequency of actionable genotypes or phenotypes 
was 25% (interquartile range 7–26%). Statins (simvastatin 
Figure 2 Drug-gene interactions (DGIs) in the study. Flowchart of DGIs and drugs identified using Clinical Pharmacogenetics 
Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) guidelines. Some drugs were excluded 
because there was no information in MEDSTAT for these drugs, possibly due to no market authorization in Denmark, no sale, no data, 
or no calculation available. The figure was build using CPIC and DPWG guidelines and data from MEDSTAT.12–14,24,29 
Possible drug-gene interacons
CPIC: 74 DGIs (47 drugs)
DPWG: 104 DGIs (83 drugs)
Unique: 134 DGIs (99 drugs)
No drug-gene interacon
DPWG: 25 DGIs (22 drugs)
Not aconable drug-gene interacon
Aconable drug-gene interacon
CPIC: 65 DGIs (46 drugs)
DPWG: 58 DGIs (50 drugs)
Unique: 87 DGIs (68 drugs)
Data available (aconable)
Unique: 49 DGIs (41 drugs)
Excluded
Unique: 38 DGIs (27 drugs)
CPIC: 9 DGIs (9 drugs)
DPWG: 21DGIs (21 drugs)
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(124,182) and atorvastatin (95,912)), metoprolol (73,531), 
tramadol (69,835), and pantoprazole (69,657) had the most 
estimated users with an actionable genotype or phenotype. 
Among psychotropics, (es-)citalopram, venlafaxine, and 
amitriptyline had the most estimated users with an action-
able genotype or phenotype, varying from 8,766 users of 
amitriptyline to 50,152 users of citalopram.
Sex differences in actionable drug-gene interactions
An overview of sex ratio per DGI indicating sex differences 
is shown in Figure 4. Six of 41 drugs were used more than 
twice as much in women. The median sex ratio in favor 
of women was 1.7 over 25 drugs, and in favor of men 1.2 
over 16 drugs. The most used actionable PGx drugs in 
women were progestogens and estrogens (contraceptives) 
with 325,251 users in 2017, followed by the proton-pump 
inhibitor pantoprazole (173,245) and simvastatin (164,605). 
In men, the three most frequently used drugs were the 
cholesterol-lowering drugs simvastatin (176,800) and ator-
vastatin (148,900), followed by pantoprazole (138,701). 
More specifically, beyond the expected sex differences in 
users of progestogens and estrogens and the anti-estrogen 
tamoxifen, the anti-emetic drug ondansetron and the anti-
depressant doxepin were used more than twice as much in 
women. The antigout drug allopurinol was more frequently 
used in men (3.5 times).
Age differences in actionable drug-gene interactions
Actionable PGx drugs were most frequently used by 
45–64 year old patients (32%) and 65–79 year old patients 
(30%), followed by 25–44 year old patients (18%). Actionable 
drugs were only used by 4, 4, and 12% of the 0–17 year old 
Figure 3 Actionable genotypes or phenotypes. The figure shows actionable genotypes or phenotypes (metabolizer status, transport 
activity, sensitivity, or genotype, expresser, or carrier status) of actionable drug-gene interactions. The figure was build using Clinical 
Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) guidelines.12–14,29 
Estrogens*: Contraceptives with estrogens (i.e.< progestogens and estrogens). het, heterozygous (yellow); hom, homozygous (red); 
IM, intermediate metabolizer (yellow); PM, poor metabolizer (red); transp., transporter (yellow); UM, (ultra)rapid metabolizers (blue).
HLA-B
CYP2D6
CYP2C19
SLCO1B1
TPMT
NUDT15
HLA-A
DPYD
F5/FvL
VKORC1
CYP3A5
CYP2C9
CYP4F2
carrier *58:01
carrier *15:02
carrier *15:11
carrier *57:01
PM
IM
UM
PM
UM
IM
poor transp. activity
intermediate transp. activity
PM
IM
PM
IM
carrier *31:01
homozygote
heterozygote
homozygote
heterozygote
high sensitivity
hom-expresser
het-expresser
PM
IM
IM
PM
allopurinol
carbamazepine
lamotrigine
oxcarbazepine
carbamazepine
flucloxacillin
amitriptyline
aripiprazole
atomoxetine
clomipramine
codeine
doxepin
flecainide
fluvoxamine
haloperidol
imipramine
metoprolol
nortriptyline
paroxetine
pimozide
propafenone
tamoxifen
tramadol
venlafaxine
zuclopenthixol
amitriptyline
atomoxetine
clomipramine
codeine
doxepin
flecainide
imipramine
metoprolol
nortriptyline
pimozide
propafenone
tamoxifen
tramadol
venlafaxine
zuclopenthixol
amitriptyline
atomoxetine
clomipramine
codeine
doxepin
flecainide
haloperidol
imipramine
metoprolol
nortriptyline
ondansetron
paroxetine
propafenone
tramadol
venlafaxine
zuclopenthixol
amitriptyline
citalopram
clomipramine
clopidogrel
doxepin
escitalopram
imipramine
sertraline
voriconazole
amitriptyline
citalopram
clomipramine
doxepin
escitalopram
imipramine
lansoprazole
omeprazole
pantoprazole
voriconazole
citalopram
clopidogrel
escitalopram
voriconazole
atorvastatin
simvastatin
atorvastatin
simvastatin
azathioprine
azathioprine
azathioprine
azathioprine
carbamazepine
fluorouracil
fluorouracil
estrogens
estrogens
phenprocoumon
warfarin
tacrolimus
tacrolimus
warfarin
warfarin
warfarin
warfarin
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patients, 18–24 year old patients, and 80+ year old patients, 
respectively. Individual drugs though show a different 
age pattern. For example, atomoxetine had 90% of users 
younger than 45 years, with 34% of users between 0 and 
17 years old. In addition, 94% of progestogens and estro-
gens users were younger than 45 years. On the other hand, 
95% of haloperidol users were 45 years or older, with 42% 
of the users being 80 + year old patients, followed by 34% 
of users being 65–79  year old patients. The top 10 most 
used drugs in children (0–17 year olds) were progestogens 
and estrogens, omeprazole, atomoxetine, pantoprazole, 
sertraline, lamotrigine, flucloxacillin, tramadol, codeine, and 
lansoprazole, respectively.
Actionable drug-gene interactions in psychotropics
Almost half of the actionable PGx drugs (19/41) in this study 
were psychotropics (i.e., antidepressants, antipsychotics, 
or psychostimulants). Of the 19 psychotropic drugs, ser-
traline and citalopram had the highest number of users. 
Psychotropic drugs were used more often by women (fac-
tor 1.7). Only atomoxetine and pimozide were used more 
frequently by men, by a factor 1.4 and 1.1, respectively 
(Figure 4).
DISCUSSION
Current knowledge on PGx originates mostly from small 
and selected patient cohorts, and little is known about 
the potential impact of PGx on population level, possibly 
hindering implementation of PGx in clinical care.36 In this 
study, we visualized the possible impact of PGx in pri-
mary care in the population of Denmark by determining the 
number of prescription drug users of 49 actionable DGIs, 
stratified on age and sex in 2017.
It was stated previously that > 95% of patients carry at 
least one actionable PGx variant, yet the combination of car-
rying a variant and taking the associated drug is important 
for it to have clinical impact.37,38 In this study, we identified 
an estimated median frequency of actionable genotypes or 
phenotypes within 49 DGIs (41 drugs) of 25%. Thus, one of 
four patients using one of these 41 PGx drugs would require 
intervention (e.g., a dose adjustment). The possible use of 
PGx in primary care was previously studied by Bank et al.9 
They investigated the number of new prescriptions of 45 
PGx primary care drugs in The Netherlands, and estimated 
that 22.9% of these patients have actionable genotypes 
or phenotypes (5.4% of 23.6%).9 Van der Wouden et al.36 
identified 24.2% actionable genotypes or phenotypes in a 
real-world impact study including 200 patients in primary 
care. Alshabeeb et al.39 identified 24.1% of prescription 
drug exposures in a 7-year period in the Dutch population 
with European ancestry (85%) to have clinical significance 
(actionable). Some differences may exist between Denmark 
and The Netherlands in prescribing or marketing of certain 
drugs for which PGx guidelines are available, and, in the 
current study, the total Danish population and CPIC PGx 
guidelines were taken into account. Still, the results are 
similar. Possibly, the frequency of actionable genotypes or 
Table 1 Estimated white population frequencies of phenotypes
Genes/enzymes PM IM EM UM References
CYP2C9 0.0707 0.294 0.635   9,10,29
CYP2C19 0.0270 0.251 0.499 0.223 9,10,2
CYP2D6 0.0547 0.179 0.707 0.03 9,10,29
DPYD 0.0076 0.038 0.954   9,10
TPMT 0.0037 0.116 0.879   9,29
CYP4F2 0 0.299 0.711   29
NUDT15 0.000015 0.008 0.986   29
fVL/F5   0.0094 0.105 0.916 30,31,35
Genes Carrier Noncarrier     References
HLA-A*31:01 0.028 0.972     29
HLA-B*15:02 0.00036 0.9996     29
HLA-B*57:01 0.032 0.968     29
HLA-B*58:01 0.013 0.987     29
HLA-B*15:11 0.003 0.997     33
Gene Poor TA Intermediate TA Normal TA   References
SLCO1B1 0.139 0.225 0.734   9,10
Genes/enzymes High sensitivity Normal sensitivity     References
VKORC1 0.159 0.835     9,10
Genes/enzymes Non-expresser Het-expresser Hom-expresser   References
CYP3A5 0.720 0.269 0.071   9,10,29,32
Estimated white population frequencies of phenotypes (EM, IM, PM, UM) were searched in literature and averages are shown in the table.
EM, extensive metabolizers; het, heterozygous; hom, homozygous; IM, intermediate metabolizers; PM, poor metabolizers; TA, transporter activity; UM, (ultra)
rapid metabolizers.
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phenotypes might differ when other PGx guidelines are in-
cluded, even though there is considerable overlap between 
available PGx guidelines.
In the stratified analyses by sex and age groups, we found 
a slightly higher prevalence in drug use in women compared 
with men. We note that women are not over-represented in 
the general Danish population (factor 1.01).34 The higher use 
might possibly be explained by sex differences in disease 
prevalence or treatment of these diseases with the included 
drugs, or the fact that there are more elderly women, and 
the elderly often use more drugs.34,40–42 The highest number 
of drug users was found in middle-aged patients, whom are 
not over-represented in the Danish population.34 A possi-
ble reason could be the disease treatment indications of 
the drugs and the increasing number of long-term chronic 
diseases in middle-aged individuals.43 Only 4% of the drug 
users were aged below 17 years. The top 10 drugs pattern 
differed between all age groups and children (0–17 year old 
patients) in four drugs; children used atomoxetine, sertraline, 
lamotrigine, and flucloxacillin more often. PGx dosing rec-
ommendations though do not comment on the drug users’ 
age. Different dosages can be used when treating children 
Figure 4 Heat-map of number of users of actionable drug-gene interactions (DGIs). The figure shows a list of actionable 
pharmacogenetics drugs included in this study. Drugs are sorted on anatomic therapeutic chemical (ATC) code and shown per 
ATC drug class. For each DGI, the (i) total number of drug users, (ii) total estimated number of users with an actionable genotype or 
phenotype, (iii) the estimated ratio of actionable genotypes or phenotypes, (iv) sex ratio in favor of women, and (v) estimated number 
of users with an actionable genotype- or phenotype per age group are shown. Data originate from the population of Denmark in 2017 
(MEDSTAT)24 and is calculated using Figure 3 and Table 1 and Table S1. Age groups are 0–17, 18–24, 25–44, 45–64, 65–79 years, and 
80 years or older. Drugs in dark blue are psychotropic drugs. 1Contraceptives with estrogens (i.e., progestogens and estrogens). A, 
alimentary tract and metabolism; Act, actionables; B, blood and blood forming organs; C, cardiovascular system; Freq, frequency; G, 
genito urinary system and sex hormones; J, general anti-infectives for systemic use; L, antineoplastic and immunomodulating agents; 
M, musculo-skeletal system; N, nervous system; ND, not done, cannot divide by 0 users.
Class Drug Gene/Enzyme Total users Total Act. 
Users
Freq. Act. Sex rao 0-17y Act. 18-24y Act. 25-44y Act. 45-64y Act. 65-79y Act. ≥80y Act.
A Omeprazole CYP2C19 130485 29137 22% 1.4 959 806 4333 10121 9548 3370
A Pantoprazole CYP2C19 311945 69657 22% 1.2 652 2196 10898 24187 22295 9429
A Lansoprazole CYP2C19 144590 32287 22% 1.3 246 794 4619 12092 10793 3744
A Ondansetron CYP2D6 11945 358 3% 3.0 16 24 90 88 91 49
B Clopidogrel CYP2C19 119735 33234 28% 0.8 3 21 670 8571 15788 8181
B Warfarin VKORC1 74170 11760 16% 0.6 18 41 372 2025 5737 3567
B Warfarin CYP2C9 74170 27070 36% 0.6 42 95 856 4661 13206 8210
B Warfarin CYP4F2 74170 22177 30% 0.6 34 78 701 3818 10819 6726
B Phenprocoumon VKORC1 1325 210 16% 0.6 0 1 9 52 93 55
C Propafenone CYP2D6 465 123 26% 0.9 0 0 1 37 69 16
C Flecainide CYP2D6 2975 784 26% 0.8 4 3 29 316 386 46
C Metoprolol CYP2D6 279055 73531 26% 1.3 108 307 2466 20391 34416 15843
C Simvastan SLCO1B1 341395 124182 36% 0.9 2 45 3105 38228 62314 20488
C Atorvastan SLCO1B1 263675 95912 36% 0.8 16 135 3790 37721 45360 8890
G Estrogens1 F5/FvL 325310 37215 11% 6023.2 5158 15515 14994 1545 3 0
J Flucloxacillin HLA-B 17900 578 3% 0.9 42 36 115 168 144 74
J Voriconazole CYP2C19 35 18 50% 0.9 0 0 3 8 8 0
L Fluorouracil DPYD 1060 48 5% 0.8 0 0 0 7 28 13
L Tamoxifen CYP2D6 785 183 23% 22.0 0 6 138 13 9 18
L Tacrolimus CYP3A5 10 3 34% /0 2 0 0 2 0 0
L Azathioprine TPMT 8315 996 12% 1.1 51 99 303 313 189 40
L Azathioprine NUDT15 8315 64 1% 1.1 3 6 19 20 12 3
M Allopurinol HLA-B 58225 766 1% 0.3 0 2 39 236 349 139
N Codeine CYP2D6 116315 30649 26% 1.9 299 834 5053 11237 9470 3756
N Tramadol CYP2D6 265030 69835 26% 1.3 323 1872 12830 25308 20362 9141
N Carbamazepine HLA-B 8320 28 0.3% 0.97 1 1 4 12 8 2
N Carbamazepine HLA-A 8320 236 3% 0.97 6 5 34 103 69 19
N Oxcarbazepine HLA-B 5300 2 0.04% 0.8 0 0 0 1 0 0
N Lamotrigine HLA-B 41875 15 0.04% 1.5 1 1 5 5 2 1
N Haloperidol CYP2D6 6285 532 8% 1.03 0 3 22 99 183 225
N Zuclopenthixol CYP2D6 4475 1179 26% 1.1 0 20 194 573 319 74
N Pimozide CYP2D6 620 145 23% 0.90 9 11 28 49 32 16
N Aripiprazole CYP2D6 11895 650 5% 1.2 44 89 249 195 55 17
N Citalopram CYP2C19 100130 50152 50% 1.9 75 1295 9371 17087 13937 8387
N Paroxene CYP2D6 12935 1095 8% 1.9 1 26 238 494 272 64
N Sertraline CYP2C19 100920 2721 3% 1.7 64 259 883 820 464 232
N Fluvoxamine CYP2D6 180 10 5% 2.1 0 0 4 3 2 1
N Escitalopram CYP2C19 24015 12028 50% 1.7 25 516 2908 4360 2790 1430
N Venlafaxine CYP2D6 50155 13216 26% 1.9 11 520 3825 5519 2615 726
N Atomoxene CYP2D6 9125 2404 26% 0.7 810 559 797 232 7 0
N Imipramine CYP2C19 4085 1022 25% 1.6 30 19 155 392 319 108
N Imipramine CYP2D6 4085 1076 26% 1.6 32 20 163 412 336 113
N Clomipramine CYP2D6 2780 733 26% 2.1 0 20 153 294 216 50
N Clomipramine CYP2C19 2780 696 25% 2.1 0 19 145 279 205 48
N Amitriptyline CYP2D6 35025 9229 26% 1.6 45 216 1714 3960 2455 839
N Amitriptyline CYP2C19 35025 8766 25% 1.6 43 205 1628 3762 2331 797
N Nortriptyline CYP2D6 14965 3943 26% 1.8 25 88 859 1706 951 314
N Doxepin CYP2D6 485 128 26% 2.4 0 0 7 29 62 30
N Doxepin CYP2C19 485 121 25% 2.4 0 0 6 28 59 29
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and PGx dose reductions may also be applied to children 
if the gene is expected to have the same functional impact 
in children and adults. This is probably the case for, as an 
example, CYP2D6 and CYP2C19, which are expressed in 
children on a similar level as adults.44 However, for the ma-
jority of commonly used drugs which have a DGI, more data 
are required to support PGx implementation in children.44
The discussion regarding the methodology of PGx tests 
and the optimal timing (i.e., pre-emptive, “as needed,” or re-
active testing) is ongoing.20,21,45 The data shown in our study 
would advocate for testing a panel of genes instead of a 
 single-gene test, as many DGIs were identified and it is likely 
people will use more than one of these drugs in their lifetime. 
Together with improving sequencing techniques (both in 
quality and price) and a more favorable cost and benefit eval-
uation, testing a panel of genes would be the best choice for 
applying PGx.21,45,46 A cost-benefit evaluation based on the 
presented data was outside of the scope of this work. Current 
PGx dosing recommendations mainly focus on drug metab-
olizing enzymes, and, thus, PK-related DGIs, which might 
extend to more recommendations involving transporters and 
receptors in the future. Testing a panel of genes would be 
even more beneficial with the expected increasing number of 
PGx guidelines. The data shown in our study suggest to test 
at the time of the first PGx drug prescription (“as needed”), 
with PGx results ready prior to start of therapy, instead of 
early execution of a PGx test prior to any first drug prescrip-
tion (pre-emptive testing) or reactive PGx testing after start 
of therapy. Depending on the timing of the first prescription 
of a drug for which a DGI is known, some patients will need 
a PGx test quite early on in life and some might never need 
a PGx test in their lifetime; but most patients will first require 
it as an adult. Therefore, pre-emptive PGx testing cannot be 
suggested for everyone at one specific age (e.g., 18 years).
The impact of PGx on the public health is insufficiently in-
vestigated. Although it is the individual patient who is affected 
and would benefit from therapeutic recommendations, it is 
the population perspective that could really improve preci-
sion medicine.47 The overall importance of this study was to 
better visualize the possible impact of PGx on public health, 
therefore, we identified all PGx prescription drug users of 
the total Danish population (n = 5,748,769). Previously, three 
larger studies were executed.9,10,39 Because we used the 
data of the total Danish population, we eliminated the risk 
for selection bias of specific drug users. Samwald et al.10 
used a combination of selected sources (private insurance 
data, Medicaid, and Medicare data), which could introduce 
selection bias in their study population by lacking a popula-
tion-representative sample. Bank et al.9 were able to include 
data of 94.4% of the pharmacies in The Netherlands, and 
expect the missing data are likely originating from outpatient 
pharmacies, dispensing more specialized pharmacother-
apy. Alshabeeb et al. focused on prescription drug users in 
The Netherlands with a European ancestry (85%) only. They 
used genotype data of 498 Dutch people to define frequen-
cies of actionable variants, which may be too small a sample 
size and not be representative for the whole population.
Our study also has some limitations. First, data on the num-
ber of users were only available for primary sector data, thus 
investigated DGIs from drugs used outside of the hospital 
sector, whereas actionable DGIs also exist for drugs used in 
hospital care but could not be included in this study. Data were 
unavailable in MEDSTAT for 27 of 68 drugs (39.7%), some of 
these drugs are likely nonprimary care drugs, whereas others 
were not marketed or sold at all in Denmark in 2017. The es-
timated impact of PGx would likely increase if hospital care 
drugs were included, as it is known there are PGx dosing 
recommendations for hospital drugs as well. Second, only 
the total (aggregated) number of drug users was available, 
no individual drug data. This made it impossible to determine 
how many drug users filled prescriptions of more than one ac-
tionable drug, or to calculate incidence instead of prevalence. 
Third, there were no genetic data available for the drug users 
in this study, thus we relied on allele frequencies of genetic 
variants based on literature. Van Driest et al. showed that 
literature allele frequencies were concordant to frequencies 
identified in 9,589 genotyped patients in the United States.48 
In addition, we assume these estimated frequencies repre-
sent our study population, as the Danish population mostly 
consists of white people, as did the study samples in most of 
the used literature.9,10,29–33,35 Fourth, we did not include data 
of nonactionable DGIs, and were, thus, unable to estimate the 
share of PGx drugs in the total drug industry. Finally, we only 
looked at the number of users of actionable DGIs and action-
able genotypes or phenotypes. We did not calculate numbers 
based on the type of PGx advice on drug use outcomes, 
as the advice may differ between PGx consortia. In some 
cases, the PGx advice is to perform additional monitoring 
(e.g., flecainide CYP2D6 UM), sometimes a dose adjustment 
is advised (e.g., azathioprine thiopurine S-methyltransferase 
intermediate metabolizer) and, in some cases, an alternative 
drug is required (e.g., abacavir HLA-B*5701 carrier).28 These 
differences are based on characteristics of the involved drug 
(e.g., therapeutic index), severity and type of side effects, and 
identified genotype or phenotype. Neglecting a PGx recom-
mendation in case of expected lack of efficacy or a relatively 
mild side effect compared with a life-threatening adverse 
event can make a huge difference in the possible impact of 
PGx. An example is the difference between UGT1A1 poor 
metabolizers using a lower dose of the cytostatic irinotecan 
to prevent life-threatening myelosuppression compared with 
CYP2C19 UMs using the proton-pump inhibitor lansoprazole, 
which might not be effective with the standard dose.
CONCLUSION
This is the first study using an unselected national popu-
lation to describe the number of users of prescription PGx 
drugs that have actionable DGIs. We found PGx testing can 
have a substantial impact on the population, with an es-
timated one of four drug users who could receive a PGx 
recommendation based on currently available PGx dosing 
guidelines. We advocate for prospective panel-based PGx 
testing at the time of the first PGx drug prescription (“as 
needed”), with PGx results ready prior to start of the first, 
and all future, therapies.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
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